Prevention of Stroke in intracerebral hemorrhage survivor with Atrial Fibrillation (PRESTIGE-AF)
Funded by the European Commission, the PRESTIGE-AF study has been set up to help prevent stroke in patients with existing conditions.
The project is aimed at patients with atrial fibrillation (AF), a common heart condition which causes irregular and abnormally fast heartbeat, and who have previously had a stroke caused by bleeding in the brain (termed intracerebral haemorrhage or ICH). The research brings together scientists and clinicians across Europe with the goal of reducing the risk of further stroke in this group of patients.
Stroke is one of the largest public health challenges, and occurs when the blood supply to the brain is interrupted, such as through a clot or a brain bleed. It is the most common cause of adult-acquired disability, the second leading cause of death globally and the second most frequent cause of dementia. In addition, its impact is expected to further increase in the coming decades due to the ageing population.
At the core of the PRESTIGE-AF project will be a clinical trial to gather evidence around recommended medication for stroke prevention in patients with AF. Several sub-studies will explore individual predictive risk modelling using brain imaging, genetic testing and other biological markers. Other aspects of the project will include exploring cognitive and psychological factors and drug adherence by patients.
The five-year project led by Professor Roland Veltkamp from the Department of Medicine at Imperial College London and involves 11 other partner institutions throughout the UK and across Europe. Professor Veltkamp said: ‘Prevention of stroke is challenging in vulnerable stroke patients with multiple disorders and interacting risks. It’s this complexity that makes it difficult to work out the best individual preventive strategy for a particular patient. Working with our international partners through the PRESTIGE-AF initiative we hope to tackle some of the unmet needs of these patients and develop more personalised treatments. Prevention is key, and ultimately we aim to prevent stroke and the impact it has on patients’ lives.
SAFE is responsible for disseminating information about PRESTIGE-AF to the stroke community. For more information, please contact email@example.com.
PRESTIGE-AF has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754517.
You can find more information on their website here: https://www.prestige-af.org/